Cephalexin for Sinusitis
Cephalexin is NOT recommended as first-line therapy for acute bacterial sinusitis in either adults or children because it lacks reliable activity against the key pathogens Haemophilus influenzae and Moraxella catarrhalis, which together account for 40–50% of cases. 1, 2
Why Cephalexin Is Not Guideline-Recommended
First-generation cephalosporins (including cephalexin) are specifically excluded from guideline recommendations for acute bacterial sinusitis because they do not adequately cover H. influenzae and M. catarrhalis. 1, 2
Amoxicillin (with or without clavulanate) is the first-line agent for both adults and children, with second- or third-generation cephalosporins (cefdinir, cefpodoxime, cefuroxime) reserved for penicillin-allergic patients. 1, 2, 3, 4
The predominant bacterial pathogens in acute sinusitis are Streptococcus pneumoniae (≈30%), H. influenzae (≈20%), and M. catarrhalis (≈20%). 2, 3 Cephalexin has good activity against S. pneumoniae but insufficient coverage of the other two. 5
If Cephalexin Must Be Used (Off-Guideline)
Adults
- Dose: 250–500 mg orally every 6 hours (1–2 g/day total). 6
- Duration: 10–14 days minimum, or at least 7 days after symptom resolution. 2, 3
- Severe infections: May increase to 500 mg every 6 hours (2 g/day), though doses >4 g/day require parenteral cephalosporins. 6
Pediatric Patients
- Dose: 25–50 mg/kg/day divided every 6 hours (QID) or every 12 hours (BID) for streptococcal pharyngitis and skin infections. 6
- Severe infections: May double the dose. 6
- Duration: 10–14 days minimum. 1, 2, 3
- Otitis media (related indication): 75–100 mg/kg/day in 4 divided doses. 6
Renal Impairment
- Creatinine clearance <30 mL/min: Reduce dose proportionally to the degree of renal dysfunction; monitor serum creatinine or creatinine clearance. 7
- Cephalexin is 70–100% renally excreted unchanged within 6–8 hours. 7
Beta-Lactam Allergy
- Non-severe penicillin allergy (isolated rash, mild GI upset): Second- or third-generation cephalosporins (cefdinir, cefpodoxime, cefuroxime) have only 1–3% cross-reactivity and are preferred over cephalexin. 1
- Severe penicillin allergy (anaphylaxis, Stevens-Johnson syndrome, DRESS): Avoid all beta-lactams, including cephalexin; use macrolides (clarithromycin or azithromycin) despite higher S. pneumoniae resistance. 1
Common Pitfalls When Using Cephalexin for Sinusitis
Failure against H. influenzae: Cephalexin fails in approximately 50% of H. influenzae infections, which are common in otitis media and sinusitis. 5
Inappropriate macrolide substitution: Macrolides are prescribed in ≈25% of sinusitis cases despite guideline recommendations against them due to high S. pneumoniae resistance (>30%); they should be reserved only for documented severe beta-lactam allergy. 1, 8
Excessive treatment duration: Approximately 75% of prescriptions exceed the recommended 10–14 day course, increasing resistance and adverse effects. 1
Preferred Guideline-Concordant Alternatives
First-Line Therapy
- Amoxicillin: 45 mg/kg/day (standard dose) or 90 mg/kg/day (high dose for resistant organisms) in children; 500 mg TID or 875 mg BID in adults. 2, 3, 4
- Amoxicillin-clavulanate: Preferred by IDSA for empiric therapy; 90 mg/kg/day (amoxicillin component) in high-risk children. 2, 4
Penicillin-Allergic Patients (Non-Severe)
- Cefdinir, cefpodoxime, or cefuroxime axetil (second- or third-generation cephalosporins) provide reliable coverage of all three key pathogens with low cross-reactivity. 1, 2, 4
Severe Penicillin Allergy
- Clarithromycin or azithromycin (macrolides) are the only recommended alternatives, though resistance is high. 1
- Avoid: Trimethoprim-sulfamethoxazole and fluoroquinolones (the latter are contraindicated in children). 1, 3
Parenteral Option
Clinical Indications for Antibiotic Therapy
- Persistent illness: Nasal discharge or daytime cough ≥10 days without improvement. 2, 3
- Severe onset: Fever ≥39°C for ≥3 consecutive days plus thick, colored nasal discharge. 2, 3
- Worsening course: New fever ≥38°C or increased cough/discharge after initial viral improvement. 2, 3